Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Inhibits MASP-2, the effector enzyme of the lectin pathway of complement, blocking lectin-dependent activation of complement components C3 and C4 without inhibiting the classical or alternative complement pathways.
Indications / reported uses
Treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and paediatric patients aged 2 years and older under the US YARTEMLEA indication (approved 23 December 2025)
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Narsoplimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Narsoplimab Permitted Daily Exposure (PDE) report (the Narsoplimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Narsoplimab Occupational Exposure Limit (OEL) report (the Narsoplimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.